Standards; Isotopic Labeled Analogues; Pharmaceutical/API Drug Impurities/Metabolites;
应用:
Labelled Vorapaxar (V758200). SCH-530348 is a novel antiplatelet agent undergoing development by Schering-Plough Corp for the treatment and prevention of atherothrombosis. It is currently undergoing Phase-III clinical trials for acute coronary syndrome (unstable angina/non-ST segment elevation myocardial infarction) and secondary prevention of cardiovascular events in high-risk patients.
您的位置：
